Seth G. Thacker
United States Food and Drug Administration(US)
Publications by Year
Research Areas
Systemic Lupus Erythematosus Research, Atherosclerosis and Cardiovascular Diseases, Cholesterol and Lipid Metabolism, Biosimilars and Bioanalytical Methods, CAR-T cell therapy research
Most-Cited Works
- → A Distinct Subset of Proinflammatory Neutrophils Isolated from Patients with Systemic Lupus Erythematosus Induces Vascular Damage and Synthesizes Type I IFNs(2010)684 cited
- → HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells(2014)412 cited
- → Interferon-α promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis(2007)274 cited
- → Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction(2016)211 cited
- → Inflammasome Activation of IL-18 Results in Endothelial Progenitor Cell Dysfunction in Systemic Lupus Erythematosus(2011)177 cited
- → Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis(2012)140 cited
- → The Detrimental Effects of IFN-α on Vasculogenesis in Lupus Are Mediated by Repression of IL-1 Pathways: Potential Role in Atherogenesis and Renal Vascular Rarefaction(2010)132 cited
- → High‐density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation(2016)126 cited
- → The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties(2015)101 cited
- → Lipoprotein X Causes Renal Disease in LCAT Deficiency(2016)87 cited